TipRanks
Go Ultimate55% OFF

Compare BCAL Diagnostics Limited (BDX) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
AU:BDXBCAL Diagnostics LimitedAUD 0.08AUD 30.97M-4.18-6.67%―Unlock the AU:BDX analyst price target with TipRanks PremiumAU:BDXUnlock the AU:BDX top-analyst price target with TipRanks Premium
AU:HLSHealius LimitedAUD 0.51AUD 359.46M-0.86-41.07%NeutralUnlock the AU:HLS analyst price target with TipRanks PremiumAU:BDX vs AU:HLSUnlock the AU:HLS top-analyst price target with TipRanks Premium
AU:RHYRhythm Biosciences Ltd.AUD 0.06AUD 22.94M-3.56-35.71%―Unlock the AU:RHY analyst price target with TipRanks PremiumAU:BDX vs AU:RHYUnlock the AU:RHY top-analyst price target with TipRanks Premium
AU:LDXLumos Diagnostics Holdings Ltd.AUD 0.06AUD 59.29M-6.49-70.73%Moderate BuyUnlock the AU:LDX analyst price target with TipRanks PremiumAU:BDX vs AU:LDXUnlock the AU:LDX top-analyst price target with TipRanks Premium
AU:SHLSonic Healthcare LimitedAUD 19.59AUD 9.67B15.91-7.03%NeutralUnlock the AU:SHL analyst price target with TipRanks PremiumAU:BDX vs AU:SHLUnlock the AU:SHL top-analyst price target with TipRanks Premium
AU:ACLAustralian Clinical Labs LtdAUD 3.23AUD 615.51M26.7026.92%NeutralUnlock the AU:ACL analyst price target with TipRanks PremiumAU:BDX vs AU:ACLUnlock the AU:ACL top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
AU:BDXBCAL Diagnostics Limited0.08-0.01-8.70%
AU:HLSHealius Limited0.49-0.39-44.07%
AU:RHYRhythm Biosciences Ltd.0.06-0.03-29.21%
AU:LDXLumos Diagnostics Holdings Ltd.0.06-0.18-75.00%
AU:SHLSonic Healthcare Limited19.57-0.30-1.52%
AU:ACLAustralian Clinical Labs Ltd3.300.8032.11%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts